Иммунотерапия почечно-клеточного рака. Современное состояние проблемы и перспективные направления исследований
- Авторы: Молчанов О.Е.1
-
Учреждения:
- ФГБУ «Российский научный центр радиологии и хирургических технологий им. акад. А.М. Гранова» Минздрава России
- Выпуск: Том 8, № 3 (2018)
- Страницы: 67-79
- Раздел: Статьи
- URL: https://bakhtiniada.ru/uroved/article/view/10464
- DOI: https://doi.org/10.17816/uroved8367-79
- ID: 10464
Цитировать
Полный текст
Аннотация
В обзоре рассмотрены современные варианты иммунотерапии больных с диссеминированными формами почечно-клеточного рака. Приведены данные экспериментальных исследований, касающиеся дефектов иммунокомпетентных клеток и механизмов, блокирующих нормальный иммунный ответ у носителей опухолей. Проанализированы данные завершенных клинических исследований блокаторов коингибирующих молекул и цитокинов у больных почечно-клеточным раком.
Полный текст
Открыть статью на сайте журналаОб авторах
Олег Евгеньевич Молчанов
ФГБУ «Российский научный центр радиологии и хирургических технологий им. акад. А.М. Гранова» Минздрава России
Автор, ответственный за переписку.
Email: molchanovo@mail.ru
д-р мед. наук, руководитель отдела фундаментальной медицины, руководитель группы молекулярно-биологического прогнозирования и индивидуализации лечения
Россия, Санкт-ПетербургСписок литературы
- Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN2012. Int J Cancer. 2015;136(5):359-386. doi: 10.1002/ijc.29210.
- Abe H, Kami T. Recent advances in the treatment of metastatic renal cell carcinoma. Int J Urol. 2013;20(10):944-955. doi: 10.1111/iju.12187.
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674. doi: 10.1016/j.cell.2011.02.013.
- Harshman LC, Drake CG, Choueiri TK. PD-1 blockade in renal cell carcinoma: to equilibrium and beyond. Cancer Immunol Res. 2014;2(12):1132-1141. doi: 10.1158/2326-6066.CIR-14-0193.
- Kulbe H, Levinson N, Balkwill F, Wilson JL. The chemokine network in cancer - much more than directing cell movement. Int J Dev Biol. 2004;48(5-6):489-496. doi: 10.1387/ijdb.041814hk.
- Rundhaug J. Matrix metalloproteinases, angiogenesis, and cancer. Clin Cancer Res. 2003;9(3):551-554.
- Egeblad M, Werb Z. New functions of metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2(3):161-174. doi: 10.1038/nrc745.
- Folgueras A, Pendas A, Sanchez L, Lopez-Otin T. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol. 2004;48(5-6):411-424. doi: 10.1387/ijdb.041811af.
- Hynes R. A reevaluation of integrins as regulators of angiogenesis. Nat Med. 2002;8(9):918-921. doi: 10.1038/nm0902-918.
- Fredman P, Hedberg K, Brezicka T. Gangliosides as therapeutic targets for cancer. BioDrugs. 2003;17(3):155-167. doi: 10.2165/00063030-200317030-00002.
- Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23(11):549-555. doi: 10.1016/s1471-4906(02)02302-5.
- Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest. 2007;117(5):155-166. doi: 10.1172/jci31422.
- Lamagna C, Aurrand-Lions M, Imhof B. Dual role of macrophages in tumor growth and angiogenesis. J Leuc Biol. 2006;80(4):705-13. doi: 10.1189/jlb.1105656.
- Talks KL, Turley H, Gatter KC, et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol. 2000;157(2):411-421. doi: 10.1016/s0002-9440(10)64554-3.
- Umemura N, Saio M, Suwa T, et al. Tumor-infiltrating myeloid-derived supressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J Leuc Biol. 2008;83(5):1136-1144. doi: 10.1189/jlb.0907611.
- Kim R, Emi M, Tanabe K, Arihiro K. Potential functional role of plasmacytoid cells in cancer immunity. Immunology. 2007;121(2):149-157. doi: 10.1111/j.1365-2567.2007.02579.x.
- Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155:1151-1164.
- Wolf A, Wolf D, Steurer M, et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res. 2003;9(2):606-612.
- Lu B, Finn O. T-cell death and cancer immune tolerance. Cell Death Differ. 2007;15(1):70-79. doi: 10.1038/sj.cdd.4402274.
- Arnold R, Brenner D, Becker M, et al. How T lymphocytes switch between life and death. Eur J Immunol. 2006;36(7):1654-1658. doi: 10.1002/eji.200636197.
- Heath WR, Kurts C, Miller J, Carbone FR. Cross-tolerance: a pathway for inducing tolerance to peripheral tissue antigens. J Exp Med. 1998;187(10):1549-1553. doi: 10.1084/jem.187.10.1549.
- Reis e Sousa C. Activation of dendritic cells: translating innate into adaptive immunity. Curr Opin Immunol. 2004;16(1):21-25. doi: 10.1016/j.coi.2003.11.007.
- Watts TH. TNF/TNFR family members in costimulation of T cell response. Annu Rev Immunol. 2005;23(1):23-68. doi: 10.1146/annurev.immunol.23.021704.115839.
- Acuto O, Michel F. CD28-mediated co-stimulation: a quantitative support for TCR signaling. Nat Rev Immunol. 2003;3(12):939-951. doi: 10.1038/nri1248.
- Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23(1): 515-548. doi: 10.1146/annurev.immunol.23.021704.115611.
- Davis MM. A new trigger for T cells. Cell. 2002;110(3):285-287. doi: 10.1016/s0092-8674(02)00865-6.
- Inman BA, Frigola X, Dong H, Kwon E. Costimulation, coinhibition and cancer. Curr Cancer Drug Targ. 2007;7(1):15-30. doi: 10.2174/156800907780006878.
- Yoshimura A. Signal transduction of inflammatory cytokines and tumor development. Cancer Sci. 2006;97(6):439-447. doi: 10.1111/j.1349-7006.2006.00197.x.
- Ma W, Gilligan BM, Yuan J, Li T. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol. 2016;9(1):47-62. doi: 10.1186/s13045-016-0277-y.
- Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734-6. doi: 10.1126/science.271.5256.1734.
- Fallarino F, Fields PE, Gajewski TF. B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28. J Exp Med. 1998;188(1):205-210. doi: 10.1084/jem.188.1.205.
- Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA. 2003;100(8):4712-4717. doi: 10.1073/pnas.0830997100.
- Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;(2794):450-461. doi: 10.1016/j.ccell.2015.03.001.
- Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-2526. doi: 10.1056/nejmoa1104621.
- Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standart-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013;31(5):616-622. doi: 10.1200/jco.2012.44.6112.
- Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064-5074. doi: 10.1158/1078-0432.ccr-13-3271.
- Keir ME, Liang SC, Guleria I, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med. 2006;203(4):883-895. doi: 10.1084/jem.20051776.
- Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal cell carcinoma. N Engl J Med. 2015;373(19):1803-1813. doi: 10.1056/NEJMoa1510665.
- McDermott DF, Sosman JA, Sznol M, et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from phase Ia study. J Clin Oncol. 2016;34(8):833-842. doi: 10.1200/jco.2015.63.7421.
- Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA-4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30(8):825-830. doi: 10.1097/cji.0b013e318156e47e.
- Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-2465. doi: 10.1056/NEJMoa1200694.
- Hughes PE, Caenepeel S, Wu LC. Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer. Trends Immunol. 2016;37(7):462-476. doi: 10.1016/j.it.2016.04.010.
- Galuzzi L, Zitvogel L, Kroemer G. Immunological mechanisms underneath the efficacy of cancer therapy. Cancer Immunol Res. 2016;4(11):895-902. doi: 10.1158/2326-6066.CIR-16-0197.
- Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science. 1976;193(4257):1007-1008.
- Brisslert M, Bokarewa M, Larsson P, et al. Phenotypic and functional characterization of human CD25+ B cells. Immunology. 2006;117(4):548-557. doi: 10.1111/j.1365-2567.2006.02331.x.
- Kronin V, Vremec D, Shortman K. Dose the IL-2 receptor alpha chain induced on dendritic cells has a biological function? Int Immunol. 1998;10(2):237-240.
- Krieg C, Letourneau S, Pantaleo G, Boyman O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptor on lymphocytes and endothelial cells. Proc Natl Acad Sci USA. 2010;107(26):11906-11911. doi: 10.1073/pnas.1002569107.
- Malek TR. The biology of Interleukin-2. Annu Rev Immunol. 2008;26:453-479. doi: 10.1146/annurev.immunol.26.021607.090357.
- Rosenberg SA, Lotze MT, Muul LM, et al. Observations of the systemic administration of autologous lymphokine-activated killer cells and recombinant Interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313(23):1485-1492. doi: 10.1056/NEJM198512053132327.
- Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014;192(12):5451-5458. doi: 10.4049/jimmunol.1490019.
- Donskov F, von der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol. 2006;24(13):1997-2005. doi: 10.1200/JCO.2005.03.9594.
- Mekhail TM, Abou-Jawde RM, BouMerhi G, et al. Validation and extension of Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 2005;23(4):832-841. doi: 10.1200/JCO.2005.05.179.
- Kaufman HL. Cancer immunotherapy with interleukin-2 - The PROCLAIMSM Registry. Oncol Hematol Rev. 2016;12(2):77-79. doi: 10.17925/ohr.2016.12.02.77.
- Clark J, McDermott DF, Dutcher JP, et al. Extension of overall survival in patients with metastatic renal cell carcinoma who received HD IL-2 followed by targeted therapy and/or immune checkpoint from PROCLAIM registry. J Clin Oncol. 2016;34(15 Suppl):4548. doi: 10.1200/jco.2016.34.15_suppl.4548.
- Молчанов О.Е. Современные прогностические системы в оценке эффективности системной химиоиммунотерапии почечно-клеточного рака с использованием рекомбинантного интерлейкина-2 // Вестник Санкт-Петербургского университета. - 2013. - Серия 11. - Вып. 2. - С. 141-148. [Molchanov OE. Current prognostic models in the estimation of the effectiveness of systemic chemoimmunotherapy with interleukin-2 in patients with renal cell carcinoma. Vestnik St. Petersburg University. 2013; Seriya 11 (Issue 2):141-147. (In Russ.)]
- Молчанов О.Е., Школьник М.И. Прогностическое значение иммунологических показателей у больных с опухолями мочеполовой системы // Медицина и образование в Сибири. - 2014. - № 6. [Molchanov OE, Shkol’nik MI. Prognosticheskoe znachenie immunologicheskih pokazatelej u bol’nyh s opuholjami mochepolovoj sistemy. Medicina i obrazovanie v Sibiri. 2014;(6). (In Russ.)] Доступно по: http://www.ngmu.ru/cozo/mos/article/text_full.php?id=1594. Ссылка активна на 15.09.2018.
- Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(9):2859-2867. doi: 10.1200/jco.1999.17.9.2859.
- Osada T, Chong G, Tansik R, et al. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother. 2008;57(8):1115-1124. doi: 10.1007/s00262-007-0441-x.
- Молчанов О.Е., Гранов А.М. Способ лечения диссеминированного почечно-клеточного рака / Патент 2409382. Российская Федерация. - № 2009129923/15. Заявлено 5.08.2009; опубликовано 20.01.2011. [Molchanov OE, Granov AM. Sposob lechenija disseminirovannogo pochechno-kletochnogo raka / Patent 2409382. Russian Federation. No 2009129923/15. Stated 5.08.2009; published 20.01.2011. (In Russ.)] Доступно по: http://www.freepatent.ru/images/patents/51/2409382/patent-2409382.pdf. Ссылка активна на 15.09.2018.
- Ma W, Gilligan BM, Yuan J, Li T. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Haematol Oncol. 2016;9(1):47-62. doi: 10.1186/s13045-016-0277-y.
- Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol. 2015;33(31):3541-3544. doi: 10.1200/jco.2015.61.6870.
Дополнительные файлы
